The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer
Open accessAbstract
BACKGROUND.: Recently, it was shown that an inflammation‐based prognostic score, the Glasgow Prognostic Score (GPS), provides additional prognostic information in patients with advanced cancer. The objective of the current study was to examine the value of the GPS compared with established scoring systems in predicting cancer‐specific survival in patients with metastatic renal cancer. METHODS.: One hundred nineteen patients who underwent immunotherapy for metastatic renal cancer were recruited. The Memorial Sloan‐Kettering Cancer Center (MSKCC) score and the Metastatic Renal Carcinoma Comprehensive Prognostic System (MRCCPS) score were calculated as described previously. Patients who had both an elevated C‐reactive protein level (>10 mg/L) and hypoalbuminemia (<35 g/L) were allocated a GPS of 2. Patients who had only 1 of those 2 biochemical abnormalities were allocated a GPS of 1. Patients who had neither abnormality were allocated a GPS of 0. RESULTS.: On multivariate analysis of significant individual factors, only calcium (hazard ratio [HR], 3.21; 95% confidence interval [95% CI], 1.51–6.83; P = .002), white cell count (HR, 1.66; 95% CI, 1.17–2.35; P = .004), albumin (HR, 2.63; 95% CI, 1.38–5.03; P = .003), and C‐reactive protein (HR, 2.85; 95% CI; 1.49–5.45; P = .002) were associated independently with cancer‐specific survival. On multivariate analysis of the different scoring systems, the MSKCC (HR, 1.88; 95% CI, 1.22–2.88; P = .004), the MRCCPS (HR, 1.42; 95% CI, 0.97–2.09; P = .071), and the GPS (HR, 2.35; 95% CI, 1.51–3.67; P < .001) were associated independently with cancer‐specific survival. CONCLUSIONS.: An inflammation‐based prognostic score (GPS) predicted survival independent of established scoring systems in patients with metastatic renal cancer. Cancer 2007. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 1×
“Patients who developed other malignancies, and patients with Creactive protein measured during a course of taxane therapy were excluded from the study since they may produce a hypersensitivity reaction and elevated concentrations of interleukin-6 (Tsavaris et al, 2002; Williams et al, 2003), which is a primary mediato…”
BackgroundTNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
A systematic review of physicians' survival predictions in terminally ill cancer patients
Glare, P., Virik, K., Jones, M., Hudson, M., Eychmuller, S., Simes, J., & Christakis, N. (2003) · BMJ · doi:10.1136/bmj.327.7408.195 · Cited by 1,024
Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., & Dunlop, D. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601242 · Cited by 792
Self-citationMaltoni, M., Caraceni, A., Brunelli, C., Broeckaert, B., Christakis, N., Eychmueller, S., Glare, P., Nabal, M., Viganò, A., Larkin, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.866 · Cited by 664
Differences in Breast Cancer Stage, Treatment, and Survival by Race and Ethnicity
Li, C. I., Malone, K. E., & Daling, J. R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.49 · Cited by 662
(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
TNM Classification of Malignant Tumors.5th ed
Szucs, R. (1998) · Radiology · doi:10.1148/radiology.207.1.66 · Cited by 448
Pyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
Kotler, D. P. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-8-200010170-00015 · Cited by 386
Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., & Dunlop, D. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601789 · Cited by 359
Self-citationImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343
The role of C-reactive protein as a prognostic indicator in advanced cancer
Mahmoud, F. A., & Rivera, N. I. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0023-1 · Cited by 325
Scott, H. R., McMillan, D. C., Forrest, L. M., Brown, D. J. F., McArdle, C. S., & Milroy, R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600466 · Cited by 322
Self-citationZhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306
Crumley, A. B. C., McMillan, D. C., McKernan, M., McDonald, A. C., & Stuart, R. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602998 · Cited by 281
Self-citationMcMillan, D. C., Elahi, M. M., Sattar, N., Angerson, W. J., Johnstone, J., & McArdle, C. S. (2001) · Nutrition and Cancer · doi:10.1080/01635581.2001.9680613 · Cited by 250
Self-citationMetastatic renal carcinoma comprehensive prognostic system
and DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group, Atzpodien, J., Royston, P., Wandert, T., & Reitz, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600768 · Cited by 241
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer
Murri, A. M. A., Bartlett, J. M. S., Canney, P. A., Doughty, J. C., Wilson, C., & McMillan, D. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602922 · Cited by 211
Self-citationAndo, M., Ando, Y., Hasegawa, Y., Shimokata, K., Minami, H., Wakai, K., Ohno, Y., & Sakai, S. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2162 · Cited by 192
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-617 · Cited by 177
Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., Dagg, K., & Scott, H. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602591 · Cited by 159
Self-citationPrognostic Factors in Advanced Gastrointestinal Cancer Patients With Weight Loss
O'Gorman, P., McMillan, D. C., & McArdle, C. S. (2000) · Nutrition and Cancer · doi:10.1207/s15327914nc3701_4 · Cited by 135
Self-citationMcKeown, D. J., Brown, D., Kelly, A. U., Wallace, A. M., & McMillan, D. C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602248 · Cited by 118
Self-citationLongitudinal study of body cell mass depletion and the inflammatory response in cancer patients
McMillan, D. C., Scott, H. R., Watson, W. S., Preston, T., Milroy, R., & McArdle, C. S. (1998) · Nutrition and Cancer · doi:10.1080/01635589809514687 · Cited by 115
Self-citationElahi, M. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., & Sattar, N. A. (2004) · Nutrition and Cancer · doi:10.1207/s15327914nc4802_6 · Cited by 113
Self-citationAlbuquerque, K., Price, M. R., BADLEY, R. A., Jönrup, I., Pearson, D., Blamey, R. W., & Robertson, J. F. R. (1995) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(95)96935-7 · Cited by 64
Bromwich, E., McMillan, D. C., Lamb, G. W. A., Vasey, P. A., & Aitchison, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602152 · Cited by 58
Self-citationRegulation of interleukin-6 secretion from breast cancer cells and its clinical implications
Kurebayashi, J. (2000) · Breast Cancer · doi:10.1007/bf02967443 · Cited by 56
Ali, S. M., Harvey, H. A., & Lipton, A. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000092981.12414.7b · Cited by 46
Cited by
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Self-citationSystemic inflammation, nutritional status and survival in patients with cancer
McMillan, D. C. (2009) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32832a7902 · Cited by 1,001
Self-citationRoxburgh, C. S., & McMillan, D. C. (2010) · Future Oncology · doi:10.2217/fon.09.136 · Cited by 998
Self-citationPierce, B. L., Ballard-Barbash, R., Bernstein, L., Baumgartner, R. N., Neuhouser, M. L., Wener, M. H., Baumgartner, K. B., Gilliland, F. D., Sorensen, B. E., McTiernan, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9068 · Cited by 691
McMillan, D. C., Crozier, J. E. M., Canna, K., Angerson, W. J., & McArdle, C. S. (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0259-6 · Cited by 533
Self-citation
Metadata
- Authors
- Ramsey, S., Lamb, G. W. A., Aitchison, M., Graham, J., & McMillan, D. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-01-08
- Volume
- 109
- Issue
- 2
- Pages
- 205-212
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2036916233
- Cited by
- 334
- References
- 39
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.